Form 990-EZ for tax year 2024
Filed by NICK GILBERT NEUROFIBROMATOSIS RESEARCH INSTITUTE.
Totals
- Total revenue
- $150,000
- Total expenses
- $1
- Contributions and grants received
- $150,000
- Grants paid
- not reported
- Program service revenue
- not reported
- Membership dues (line 3)
- not reported
- Investment income (line 4)
- not reported
- Gain or loss on sale of assets (line 5c)
- not reported
- Gaming and fundraising events, net (line 6d)
- not reported
- Gross profit on inventory sales (line 7c)
- not reported
- Other revenue (line 8)
- not reported
- Total assets, end of year
- $149,999
- Total liabilities, end of year
- $0
- Net assets or fund balances, end of year
- $149,999
- Program service expenses (Part III)
- $0
Program services were 0.0% of total expenses calculated — Part III's total program service expenses over total expenses, both as filed.
Mission and programs · 2024
Primary exempt purpose
THE PRINCIPAL PURPOSE OF THE INSTITUTE IS TO ACTIVELY AND CONTINUOUSLY ENGAGE DIRECTLY IN THE CONDUCT OF MEDICAL RESEARCH, BOTH ON ITS OWN AND IN CONJUNCTION WITH ONE OR MORE HOSPITALS AND UNIVERSITIES. THE INSTITUTE HAS BEGUN ITS INITIAL EFFORTS IN SCIENTIFIC AND MEDICAL RESEARCH TO ACCELERATE THE DEVELOPMENT OF RESEARCH FINDINGS AND TECHNOLOGIES THAT WILL LEAD TO THE CREATION OF NEW MEDICINES, NEW DIAGNOSTICS, AND OTHER ENABLING PRODUCTS TO TREAT PATIENTS WITH NEUROFIBROMATOSIS ("NF") AND OTHER DEBILITATING NEURONAL DISEASES AND RELATED CONDITIONS. IN THE CURRENT YEAR, THE INSTITUTE HAS ESTABLISHED RESEARCH PARTNERSHIPS AND BEGAN CONSTRUCTION ON ITS OPERATIONAL SPACE.
-
THE PRINCIPAL PURPOSE OF THE INSTITUTE IS TO ACTIVELY AND CONTINUOUSLY ENGAGE DIRECTLY IN THE CONDUCT OF MEDICAL RESEARCH, BOTH ON ITS OWN AND IN CONJUNCTION WITH ONE OR MORE HOSPITALS AND UNIVERSITIES. THE INSTITUTE HAS BEGUN ITS INITIAL EFFORTS IN SCIENTIFIC AND MEDICAL RESEARCH TO ACCELERATE THE DEVELOPMENT OF RESEARCH FINDINGS AND TECHNOLOGIES THAT WILL LEAD TO THE CREATION OF NEW MEDICINES, NEW DIAGNOSTICS, AND OTHER ENABLING PRODUCTS TO TREAT PATIENTS WITH NEUROFIBROMATOSIS ("NF") AND OTHER DEBILITATING NEURONAL DISEASES AND RELATED CONDITIONS. IN THE CURRENT YEAR, THE INSTITUTE HAS ESTABLISHED RESEARCH PARTNERSHIPS AND BEGAN CONSTRUCTION ON ITS OPERATIONAL SPACE.
As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.
Listed in Part IV
-
LAURA GRANNEMANN
PRESIDENT, DIRECTOR
- Total calculated
- $0
- Hours/week
- 0
-
JEFFREY MORGANROTH
SECRETARY, DIRECTOR
- Total calculated
- $0
- Hours/week
- 0
-
MATTHEW RIZIK
TREASURER, DIRECTOR
- Total calculated
- $0
- Hours/week
- 0
-
DANIEL GILBERT
DIRECTOR
- Total calculated
- $0
- Hours/week
- 0
-
JENNIFER GILBERT
DIRECTOR
- Total calculated
- $0
- Hours/week
- 0
Compensation is as filed in Part IV of the Form 990-EZ: compensation, contributions to benefit plans, expense account, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total.
Grants on this return
No itemized grants to organizations on this return.
Provenance
- Return type
- form_990_ez
- Tax year
- 2024
- Filed
- 6 November 2025
- IRS schema version
- 2024v5.2
- Source object
- 202533179349203788
Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.
The source document this was parsed from is served over the API, which is where bulk and document access live.